Doctor Who Sold Matthew Perry Ketamine To Be Sentenced Wed.

Digest more
Doctor who sold ketamine to 'Friends' star Matthew Perry before his overdose death gets 2 1/2 years in prison
A doctor who pleaded guilty to selling ketamine to Matthew Perry in the weeks before the “Friends” star’s overdose death was sentenced to 2 1/2 years in prison on Wednesday. Judge Sherilyn Peace Garnett handed down the sentence plus two years of probation to 44-year-old Dr.

Continue reading

Doctor sentenced to 30 months in connection to Matthew Perry's ketamine overdose
Doctor who sold ketamine to ‘Friends’ star Matthew Perry receives 30-month sentence
'No excuse' - California doctor sentenced to 30 months in Matthew Perry overdose case
The parents of Friends star Matthew Perry have written to a judge who is set to sentence a doctor who prescribed the actor ketamine before his overdose death.

Continue reading

Former doctor who prescribed Matthew Perry ketamine sentenced to 30 months
Doctor who sold Matthew Perry ketamine in weeks leading up to his death gets 30 months in prison
Doctor who supplied Matthew Perry ketamine jailed
U.S. District Judge Sherilyn Peace Garnett handed down the sentence Wednesday to Dr. Salvador Plasencia, 44, in a federal courtroom in Los Angeles.

Continue reading

Jail sentence revealed for doctor who gave Matthew Perry ketamine
Doctor who sold ketamine to ‘Friends’ star Matthew Perry gets 2½ years in prison

Urgent warning over super strong ketamine flooding UK streets: Terrified universities issue alert after chemical turning US addicts into 'zombies' is found in drug abused by ...

Approved only for veterinary use as a sedative and painkiller, officials believe it is increasingly being mixed with other street drugs to create deadly cocktails.

PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise

Detailed price information for Pharmather Hldgs Ltd (PHRRF) from The Globe and Mail including charting and trades.

NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine

FDA has determined that NRx’s Abbreviated New Drug Application (ANDA) is “substantially complete” and received for review. Assigned GDUFA goal
Feedback